Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains

被引：0

作者：

机构：

[1] [1,Hay, Duncan A.

[2] 2,Fedorov, Oleg

[3] 2,Martin, Sarah

[4] 2,Singleton, Dean C.

[5] 2,Tallant, Cynthia

[6] 2,Wells, Christopher

[7] Picaud, Sarah

[8] 2,Philpott, Martin

[9] 2,Monteiro, Octovia P.

[10] 2,Rogers, Catherine M.

[11] Conway, Stuart J.

[12] Rooney, Timothy P. C.

[13] 2,Tumber, Anthony

[14] 2,Yapp, Clarence

[15] Filippakopoulos, Panagis

[16] Bunnage, Mark E.

[17] 2,Müller, Susanne

[18] 2,Knapp, Stefan

[19] Schofield, Christopher J.

[20] 2,Brennan, Paul E.

来源：

Brennan, P.E. (paul.brennan@sgc.ox.ac.uk) | 1600年 / American Chemical Society卷 / 136期

关键词：

Small-molecule inhibitors that target bromodomains outside of the bromodomain and extra-terminal (BET) sub-family are lacking. Here; we describe highly potent and selective ligands for the bromodomain module of the human lysine acetyl transferase CBP/p300; developed from a series of 5-isoxazolyl-benzimidazoles. Our starting point was a fragment hit; which was optimized into a more potent and selective lead using parallel synthesis employing Suzuki couplings; benzimidazole-forming reactions; and reductive aminations. The selectivity of the lead compound against other bromodomain family members was investigated using a thermal stability assay; which revealed some inhibition of the structurally related BET family members. To address the BET selectivity issue; X-ray crystal structures of the lead compound bound to the CREB binding protein (CBP) and the first bromodomain of BRD4 (BRD4(1)) were used to guide the design of more selective compounds. The crystal structures obtained revealed two distinct binding modes. By varying the aryl substitution pattern and developing conformationally constrained analogues; selectivity for CBP over BRD4(1) was increased. The optimized compound is highly potent (K d = 21 nM) and selective; displaying 40-fold selectivity over BRD4(1). Cellular activity was demonstrated using fluorescence recovery after photo-bleaching (FRAP) and a p53 reporter assay. The optimized compounds are cell-active and have nanomolar affinity for CBP/p300; therefore; they should be useful in studies investigating the biological roles of CBP and p300 and to validate the CBP and p300 bromodomains as therapeutic targets. © 2014 American Chemical Society;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Journal article (JA)

引用

共 50 条

[31] CBP/p300 BromodomainMediates Amyloid Formation
Liao, Daiqing
CELL CHEMICAL BIOLOGY, 2017, 24 (02): : 128 - 129
[32] Viral replication and the coactivators p300 and CBP
Hottiger, MO
Nabel, GJ
TRENDS IN MICROBIOLOGY, 2000, 8 (12) : 560 - 565
[33] Selective inhibition of CBP/p300 HAT
Sarli, Vasiliki
Giannis, Athanassios
CHEMISTRY & BIOLOGY, 2007, 14 (06): : 605 - 606
[34] CBP and p300: HATs for different occasions
Kalkhoven, E
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (06) : 1145 - 1155
[35] p300/CBP keeps chromatin silent
Katharine H. Wrighton
Nature Structural & Molecular Biology, 2022, 29 : 1039 - 1039
[36] Protein Lysine Acetylation by p300/CBP
Dancy, Beverley M.
Cole, Philip A.
CHEMICAL REVIEWS, 2015, 115 (06) : 2419 - 2452
[37] Update - CBP/p300 transgenic mice
Giles, RH
TRENDS IN GENETICS, 1998, 14 (06) : 214 - 214
[38] Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases
Ji, Zhiqin
Clark, Richard F.
Bhat, Vikram
Hansen, T. Matthew
Lasko, Loren M.
Bromberg, Kenneth D.
Manaves, Vlasios
Algire, Mikkel
Martin, Ruth
Qiu, Wei
Torrent, Maricel
Jakob, Clarissa G.
Liu, Hong
Cole, Philip A.
Marmorstein, Ronen
Kesicki, Edward A.
Lai, Albert
Michaelides, Michael R.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 39
[39] Small-Molecule Proteomimetic Inhibitors of the HIF-1α-p300 Protein-Protein Interaction
Burslem, George M.
Kyle, Hannah F.
Breeze, Alexander L.
Edwards, Thomas A.
Nelson, Adam
Warriner, Stuart L.
Wilson, Andrew J.
CHEMBIOCHEM, 2014, 15 (08) : 1083 - 1087
[40] Plant orthologs of p300/CBP:: conservation of a core domain in metazoan p300/CBP acetyltransferase-related proteins
Bordoli, L
Netsch, M
Lüthi, U
Lutz, W
Eckner, R
NUCLEIC ACIDS RESEARCH, 2001, 29 (03) : 589 - 597

← 1 2 3 4 5 →